# Asarina Pharma chooses YpsoMate autoinjector for Sepranolone

Asarina Pharma has decided to use Ypsomed's YpsoMate autoinjector for its phase III study and commercial launch of Sepranolone, a treatment for pre-menstrual dysphoric disorder.

- Type: Contract
- Announced: 2020-03-31
- Status: announced
- Products: YpsoMate autoinjector, Sepranolone drug
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Ypsomed](https://endata.com/companies/9625.md) (supplier)
- [Asarina Pharma](https://endata.com/companies/46218.md) (customer)

## Sources

- [ypsomed.com](https://www.ypsomed.com/en/news-insights/product-news/product-news-detail-page/asarina-has-chosen-ypsomate-as-the-injection-device-for-their-drug-sepranolone), 2020-03-31: "Asarina Pharma has decided to go with our user-friendly two-step autoinjector YpsoMate for its commercial launch of its drug Sepranolone."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.